Aurion Biotech Launches Vyznova in Japan for the Treatment of Bullous Keratopathy of the Cornea

Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced the commercial launch of Vyznova in Japan, for the treatment of bullous keratopathy of the cornea. The company believes this is the first approved cell therapy for the treatment of corneal endothelial disease; it has received both regulatory and reimbursement approval in Japan.